This content is in French.
IVIG: an ally against fever in ALL?
26 février 2025
#Leukemia #ALL #cancer #oncology #pediatrics #prophylaxis #immunoglobulin #fever
Acute lymphoblastic laukemia (ALL) is the most common pediatric cancer. Despite therapeutic advances, infections remain a major cause of complications and mortality. Approximately 20% of deaths related to pediatric hematologic cancer treatment are due to infections, accounting for more than half of non-disease-related deaths.
Intensive treatments, such as chemotherapy, weaken the immune system, leading to a decrease in immunoglobulins (IgG) and B lymphocytes, both essential for infection defense. This immune deficiency exposes children to frequent infections, often accompanied by fever requiring hospitalization. These repeated hospitalizations can interrupt chemotherapy, increasing the risk of relapse.
Acute lymphoblastic laukemia (ALL) is the most common pediatric cancer. Despite therapeutic advances, infections remain a major cause of complications and mortality. Approximately 20% of deaths related to pediatric hematologic cancer treatment are due to infections, accounting for more than half of non-disease-related deaths.
Intensive treatments, such as chemotherapy, weaken the immune system, leading to a decrease in immunoglobulins (IgG) and B lymphocytes, both essential for infection defense. This immune deficiency exposes children to frequent infections, often accompanied by fever requiring hospitalization. These repeated hospitalizations can interrupt chemotherapy, increasing the risk of relapse.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Thus, K. A., et al. (2025). Immunoglobulin prophylaxis prevents hospital admissions for fever in pediatric acute lymphoblastic leukemia: results of a multicenter randomized trial. Haematologica, 110(1), 47–54
View the source
